Intra-Cellular Therapies v. Dr. Reddy’s: ANDA Patent Fight Over CAPLYTA® Consolidated Into Multi-Defendant Lumateperone Litigation
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Intra-Cellular Therapies, Inc. v. Dr. Reddy’s Laboratories, Ltd. |
| Case Number | 3:24-cv-04314 (D.N.J.) |
| Court | District of New Jersey, consolidated into lead case 3:24-cv-04264 |
| Duration | March 2024 – August 2024 5 months |
| Outcome | Consolidated (Procedural Closure) |
| Patents at Issue | |
| Accused Products | CAPLYTA® (lumateperone) capsules (10.5 mg, 21 mg, 42 mg) |
Case Overview
The Parties
⚖️ Plaintiff
New York-based biopharmaceutical company specializing in neuropsychiatric and neurological disorders. Developer of CAPLYTA® (lumateperone).
🛡️ Defendant
Multinational pharmaceutical company with substantial U.S. generic drug operations, challenging CAPLYTA® patents via ANDA filing.
Patents at Issue
This landmark case involved 16 U.S. patents asserted by ITCI, covering the lumateperone molecule, its pharmaceutical formulations, and therapeutic use methods. This layered, multi-patent strategy is characteristic of branded pharmaceutical companies seeking to extend market exclusivity well beyond any single patent’s expiration. Patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US8648077B2 — foundational compound chemistry
- • US9199995B2 — formulation and synthesis patent
- • US9168258B2 — formulation and synthesis patent
- • US9616061B2 — formulation and synthesis patent
- • US9956227B2 — formulation and synthesis patent
- • US10117867B2 — extended pharmaceutical coverage
- • US10464938B2 — extended pharmaceutical coverage
- • US10695345B2 — extended pharmaceutical coverage
- • US10960009B2 — extended pharmaceutical coverage
- • US11026951B2 — newer method and composition claims
- • US11052084B2 — newer method and composition claims
- • US11690842B2 — newer method and composition claims
- • US11753419B2 — newer method and composition claims
- • US11806348B2 — newer method and composition claims
- • USRE048825E — reissued patent strengthening claim scope
- • USRE048839E — reissued patent strengthening claim scope
Developing a New Drug or Generic?
Ensure your product has freedom to operate against complex pharmaceutical patent portfolios.
The Verdict & Legal Analysis
Outcome
Case No. 3:24-cv-04314 was consolidated for all pretrial purposes into lead Civil Action No. 3:24-cv-04264 (ITCI v. Aurobindo) by court order dated July 16, 2024, and subsequently closed on August 5, 2024. No damages were assessed and no injunctive relief was independently granted at this stage. The case’s closure is purely procedural — substantive infringement claims against Dr. Reddy’s continue within the consolidated proceeding. No merits-based verdict, settlement amount, or damages figure has been disclosed in the available case record.
Key Legal Issues
The court’s consolidation order under Federal Rule of Civil Procedure 42 reflects a deliberate efficiency rationale. With seven defendants asserting patent invalidity and non-infringement against an overlapping set of 16 patents covering the same drug product, parallel proceedings would create redundant claim construction hearings, duplicative expert testimony, and inconsistent rulings. This consolidation pattern carries important precedential implications for pharmaceutical patent litigation strategy.
Freedom to Operate (FTO) Analysis
This consolidated ANDA litigation highlights unique IP challenges in pharmaceutical R&D and generic drug development.
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical patent litigation.
- View all 16 asserted patents
- See key prior art trends in lumateperone space
- Understand claim construction nuances
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug compound or generic formulation.
- Input your compound structure or formulation details
- AI identifies potentially blocking pharma patents
- Get actionable risk assessment report
High Risk Area
Lumateperone compound and formulations
16 Asserted Patents
Complex multi-patent strategy
Design-Around Options
Potential for method-of-treatment claims
✅ Key Takeaways
Rule 42 consolidation in multi-defendant ANDA cases is an increasingly standard efficiency mechanism in D.N.J.
Search related case law →Reissued patent claims (USRE048825E, USRE048839E) may generate intervening rights defenses worth investigating.
Explore precedents →Frequently Asked Questions
ITCI asserted 16 U.S. patents covering lumateperone compound chemistry, pharmaceutical formulations, and therapeutic methods, including reissued patents USRE048825E and USRE048839E, across consolidated ANDA litigation in the District of New Jersey.
The case was administratively closed following court-ordered consolidation under FRCP Rule 42 into lead case No. 3:24-cv-04264 on July 16, 2024. Substantive litigation against Dr. Reddy’s continues within the consolidated proceeding.
Unified claim construction and pretrial rulings in the consolidated case will apply across all seven generic defendants, making Markman hearing outcomes particularly consequential for the entire lumateperone ANDA litigation landscape.
Ready to Master Complex Pharmaceutical IP Litigation?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, manage ANDA cases, and analyze competitive landscapes with AI-powered precision.
References
- PACER — Case No. 3:24-cv-04264 (Lead Consolidated Action)
- USPTO Patent Center — US8648077B2
- FDA Orange Book — Lumateperone Listings
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 42
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.